Progenics Pharma (PGNX) Misses Q3 EPS by 1c

Progenics Pharma (NASDAQ: PGNX) reported Q3 EPS of ($0.14), $0.01 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $1.4 million versus the consensus estimate of $2.35 million.

For earnings history and earnings-related data on Progenics Pharma (PGNX) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
• JPMorgan Starts Bytes Technology Group PLC (BYIT:LN) at Underweight